Key result
Recent advances in understanding the pathophysiology of acute pancreatitis have led to the testing of inflammatory mediator antagonists in humans as potential new therapies.
Recent advances in understanding the pathophysiology of acute pancreatitis have led to the testing of inflammatory mediator antagonists as potential specific treatments.
This is the authors' abstract. We don't add key points for this paper.
The treatment of acute pancreatitis has remained virtually unchanged for the past 50 years, in large part due to a poor understanding of the initial intracellular events. Furthermore, there is a lack of knowledge regarding the mediator(s) responsible for the progression of the disease from local pancreatic inflammation to a systemic inflammatory disease, as well as the mediator(s) responsible for distant organ dysfunction and failure. With recent advances in the pathophysiology of pancreatitis, in particular the role of the inflammatory mediators interleukin-1 beta, tumour necrosis factor alpha and platelet-activating factor, the potential for new effective therapies has been realised. At present, a number of inflammatory mediator antagonists are being tested in humans, with the hope that we may soon develop a specific treatment for a disease, which thus far, has none.
Supports continued evaluation of novel agents; does not yet justify changes in acute pancreatitis management.
No takes yet. Share an insight, caveat, or question.
Denham et al. (1999) conducted a review in acute pancreatitis. Inflammatory mediator antagonists was evaluated. Recent advances in understanding the pathophysiology of acute pancreatitis have led to the testing of inflammatory mediator antagonists in humans as potential new therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: